Cargando…

Clinical impact of reducing the frequency of clozapine monitoring: controlled mirror-image cohort study

BACKGROUND: To minimise infection during COVID-19, the clozapine haematological monitoring interval was extended from 4-weekly to 12-weekly intervals in South London and Maudsley NHS Foundation Trust. AIMS: To investigate the impact of this temporary policy change on clinical and safety outcomes. ME...

Descripción completa

Detalles Bibliográficos
Autores principales:	Oloyede, Ebenezer, Dzahini, Olubanke, Abolou, Zadro, Gee, Siobhan, Whiskey, Eromona, Malhotra, Diksha, Hussain, Masuma, Osborne, Ian, Casetta, Cecilia, McGuire, Philip, MacCabe, James H., Taylor, David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cambridge University Press 2023
Materias:	Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391318/ https://www.ncbi.nlm.nih.gov/pubmed/37092691 http://dx.doi.org/10.1192/bjp.2023.44

Ejemplares similares

Clozapine haematological monitoring for neutropenia: a global perspective
por: Oloyede, Ebenezer, et al.
Publicado: (2022)

A retrospective case notes review of the effectiveness and tolerability of metoclopramide in the treatment of clozapine-induced hypersalivation (CIH)
por: Livermore, Cecilia, et al.
Publicado: (2022)

Distinctive pattern of neutrophil count change in clozapine-associated, life-threatening agranulocytosis
por: Taylor, David, et al.
Publicado: (2022)

Real-world effectiveness of admissions to a tertiary treatment-resistant psychosis service: 2-year mirror-image study
por: Casetta, Cecilia, et al.
Publicado: (2020)

The lived experience of clozapine discontinuation in patients and carers following suspected clozapine-induced neutropenia
por: Oloyede, Ebenezer, et al.
Publicado: (2023)

Management of clozapine treatment during the COVID-19 pandemic
por: Gee, Siobhan, et al.
Publicado: (2020)

Clozapine augmentation with cariprazine for negative symptoms: a case series and literature review
por: Oloyede, Ebenezer, et al.
Publicado: (2022)

Vortioxetine as adjunctive therapy in the treatment of schizophrenia
por: Redaelli, Sofia, et al.
Publicado: (2022)

Benign ethnic neutropenia: an analysis of prevalence, timing and identification accuracy in two large inner-city NHS hospitals
por: Oloyede, Ebenezer, et al.
Publicado: (2021)

Reducing the Risk of Withdrawal Symptoms and Relapse Following Clozapine Discontinuation—Is It Feasible to Develop Evidence-Based Guidelines?
por: Blackman, Graham, et al.
Publicado: (2021)

Clozapine-induced myocarditis: electronic health register analysis of incidence, timing, clinical markers and diagnostic accuracy
por: Segev, Aviv, et al.
Publicado: (2021)

What are the barriers and facilitators of clozapine use in early psychosis? A survey of UK early intervention clinicians
por: Oloyede, Ebenezer, et al.
Publicado: (2023)

Clozapine-induced myocarditis: electronic health register analysis of incidence, timing, clinical markers and diagnostic accuracy – ERRATUM
por: Segev, Aviv, et al.
Publicado: (2021)

Outcomes in treatment-resistant schizophrenia: symptoms, function and clozapine plasma concentrations
por: Krivoy, Amir, et al.
Publicado: (2021)

Clozapine for treatment resistance in early psychosis: a survey of UK clinicians’ training, knowledge and confidence
por: Oloyede, Ebenezer, et al.
Publicado: (2022)

Change in plasma concentration of clozapine and norclozapine following a switch of oral formulation
por: Keshavarzi, Farinaz, et al.
Publicado: (2020)

Successful clozapine rechallenge following recurrent clozapine-associated pancreatitis: a case report
por: Rodriguez, Victoria, et al.
Publicado: (2020)

Closure beyond clozapine: successfully averting rebound symptoms in a patient with schizoaffective disorder and agranulocytosis
por: Green, Alastair, et al.
Publicado: (2019)

Resolution without discontinuation: heart failure during clozapine treatment
por: Whiskey, Eromona, et al.
Publicado: (2020)

Possible pharmacogenetic factors in clozapine treatment failure: a case report
por: Whiskey, Eromona, et al.
Publicado: (2021)

Clozapine discontinuation withdrawal symptoms in schizophrenia
por: Blackman, Graham, et al.
Publicado: (2021)

Clozapine-induced agranulocytosis
por: Mijovic, Aleksandar, et al.
Publicado: (2020)

The side effect profile of Clozapine in real world data of three large mental health hospitals
por: Iqbal, Ehtesham, et al.
Publicado: (2020)

Rehabilitation or Stagnation? a Six Month Mirror-Image Study Reviewing the Effectiveness of an Inpatient Rehabilitation Unit
por: Kapila, Adisha, et al.
Publicado: (2022)

41. RECONSIDERING THE EVIDENCE FOR CLOZAPINE FOR TREATMENT REFRACTORY SCHIZOPHRENIA
por: MacCabe, James
Publicado: (2018)

T19. GLUTAMATE AND RESPONSE TO CLOZAPINE IN TREATMENT RESISTANT SCHIZOPHRENIA
por: Egerton, Alice, et al.
Publicado: (2020)

Clozapine Response in Schizophrenia and Hematological Changes
por: Blackman, Graham, et al.
Publicado: (2021)

Haloperidol decanoate long-acting injection (HDLAI): Results of a 1-year mirror-image study
por: Mace, Shubhra, et al.
Publicado: (2018)

41.3 COULD CLOZAPINE REDUCE VIOLENT OFFENDING?
por: Bhavsar, Vishal, et al.
Publicado: (2018)

Changes in Brain Glutamate on Switching to Clozapine in Treatment-Resistant Schizophrenia
por: McQueen, Grant, et al.
Publicado: (2021)

Clozapine and COVID-19
por: Silva, Edward, et al.
Publicado: (2020)

Establishing the characteristics of an effective pharmacogenetic test for clozapine-induced agranulocytosis
por: Verbelen, M, et al.
Publicado: (2015)

Using a statistical learning approach to identify sociodemographic and clinical predictors of response to clozapine
por: Fonseca de Freitas, Daniela, et al.
Publicado: (2022)

Biological Predictors of Clozapine Response: A Systematic Review
por: Samanaite, Ruta, et al.
Publicado: (2018)

M212. A SYSTEMATIC REVIEW AND META-ANALYSIS OF CLINICAL VARIABLES ASSOCIATED WITH RESPONSE TO CLOZAPINE IN TREATMENT RESISTANT SCHIZOPHRENIA
por: Griffiths, Kira, et al.
Publicado: (2020)

Clozapine treatment and risk of severe COVID‐19 infection
por: Ohlis, Anna, et al.
Publicado: (2021)

Clozapine treatment and risk of COVID-19 infection: retrospective cohort study
por: Govind, Risha, et al.
Publicado: (2021)

Neutropenia and agranulocytosis during treatment of schizophrenia with clozapine versus other antipsychotics: an observational study in Iceland
por: Ingimarsson, Oddur, et al.
Publicado: (2016)

Prescribing clozapine in the UK: Quality improvement issues identified by clinical audit
por: Barnes, Thomas RE, et al.
Publicado: (2022)

S146. EFFECT OF CLOZAPINE ON REGIONAL CEREBRAL BLOOD FLOW IN TREATMENT-RESISTANT SCHIZOPHRENIA
por: Sendt, Kyra-Verena, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_1v9ue42flpqrgcdrrl5amrhoqg